Top in endocrinology: Walmart’s private brand analog insulin, new data on tirzepatide
Walmart announced that insulin aspart injections are now available through its private ReliOn brand, with doses discounted from 58% to 75% off other insulin products. The announcement was the top story in endocrinology last week.
Another top story shared results from multiple SURPASS studies. The data showed that tirzepatide (Eli Lilly) improved glycemic response and weight loss in adults with type 2 diabetes without increasing the risk for hypoglycemia.
Read these and more top stories in endocrinology below:
Walmart launches first and only private brand analog insulin
Walmart announced it will partner with Novo Nordisk to launch a first-ever private brand analog insulin, retailing up to 75% off the cash price of branded insulin products, according to a press release. Read more.
SURPASS data: ‘Impressive’ tirzepatide could change goals for diabetes treatment
Data from the SURPASS clinical trial program suggest the dual incretin agonist tirzepatide could be a game-changing new therapy for adults with type 2 diabetes, many of whom experienced substantial weight loss and achieved normoglycemia. Read more.
GRADE: GLP-1 agonists, insulin more effective than other diabetes drugs
In a head-to-head study of four classes of glucose-lowering drugs, the GLP-1 receptor agonist Victoza (liraglutide, Novo Nordisk) and Lantus (insulin glargine, Sanofi) were more effective for maintaining HbA1c below 7% than a sulfonylurea or DPP-IV inhibitor. Read more.
AMPLITUDE-O: Efpeglenatide reduces CV events, CKD progression in high-risk type 2 diabetes
A novel GLP-1 receptor agonist reduced cardiovascular event risk by 27% and kidney disease progression by 32% compared with placebo for high-risk adults with type 2 diabetes, with or without background SGLT2 inhibitor therapy, data show. Read more.
Daily oral insulin improves metabolic markers in children at high risk for type 1 diabetes
Daily oral insulin therapy may improve glucose and C-peptide measurements for a subset of children at high risk for type 1 diabetes, according to new TrialNet data presented at the American Diabetes Association Scientific Sessions. Read more.